The Belgian listed biotech company Innogenetics was acquired in 2010 by the Japanese Fujirebio Inc. Innogenetics, based in Ghent, entered the global spotlight with its research on infectious diseases (HIV and hepatitis C) and Alzheimer's disease. In 2013 the company underwent a name change to Fujirebio Europe, an affiliate of the Japanese Miraca Holdings. That company has over 1.100 employees in Asia, Europe and America.
